It is currently Sun Jul 22, 2018 5:36 am

News News of Campath (Lemtrada, Alemtuzumab)

Site map of Campath (Lemtrada, Alemtuzumab) » Forum : Campath (Lemtrada, Alemtuzumab)

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

Third course of Lemtrada improves MS patient’s relapse rate

Study shows third course of Lemtrada improves MS patient’s relapse rate and disability

A study released at #ACTRIMS2018 has revealed that patients who experienced relapses after two courses of Lemtrada (alemtuzumab) showed improvement in relapse rate and disability progression after a third course of the drug…Read more - http://www.ms-uk.org/study-shows-third-course-lemtrada-improves-ms-patient%E2%80%99s-relapse-rate-and-disability

Image
Read more : Third course of Lemtrada improves MS patient’s relapse rate | Views : 1311 | Replies : 0


Report highlights Alemtuzumab as one of many 'rip-off' drugs

Report highlights MS drug Alemtuzumab as one of many 'rip-off' drugs

Multiple sclerosis (MS) drug Alemtuzumab has been highlighted as one of a number of drugs being sold at extortionate prices to rip-off the public and the NHS...Read more - http://www.ms-uk.org/report-highlights-ms-drug-alemtuzumab-one-many-rip-drugs-0

Image
Read more : Report highlights Alemtuzumab as one of many 'rip-off' drugs | Views : 1834 | Replies : 0


Day 2 of LEmtrada - Round 2

I just finished up day 2 of Lemtrada. Seems to be going ok so far except headache and lack of sleep from steroids. I got Campath during the MS Care trial in 2010 at the high dose and got ITP. Hopefully this new lower dose will not give me that but will still beat back the MS monster for a while. I sure hope so. I will follow up as things progress...

Grump -
Read more : Day 2 of LEmtrada - Round 2 | Views : 1467 | Replies : 1


Unpublished data may explain Lemtrada's efficacy...

Previously unpublished data may explain Lemtrada's efficacy and side effects

Analysis of previously unpublished data from the pivotal phase III trials in the regulatory submissions of alemtuzumab, otherwise known as Lemtrada, indicated that efficiency was associated with long-term depletion of memory T- and B-cells. Whereas rapid hyper-repopulation of immature B-cells in the relative absence of regulatory CD4 and CD8 T-cells create the environment for the generation of secondary B-cell autoimmunity, including anti-drug antibodies...Read more - ...
Read more : Unpublished data may explain Lemtrada's efficacy... | Views : 1717 | Replies : 0


MS drug Lemtrada is linked to food poisoning

A case report has revealed that a patient who was treated with alemtuzumab (Lemtrada) contracted food poisoning...Read more - http://www.ms-uk.org/ms-drug-lemtrada-linked-food-poisoning-200417
Read more : MS drug Lemtrada is linked to food poisoning | Views : 1379 | Replies : 0


Campath - retreatment after ITP the 1st time??!!

SO I was in the CARE MS trial and got the high dose for the full week. It was very effective for me neurologically, but after 6 months I got ITP, badly, and it was scary. I recovered after steroid treatments, but could not get the second treatment.

My MS has been progressing lately, mostly walking, balance, coordination, etc. My new Neuro suggests I take another dose of Campath, low dose for 3 days. I ...
Read more : Campath - retreatment after ITP the 1st time??!! | Views : 1650 | Replies : 7


Lemtrada shows promising results for RRMS patients

Two clinical trials investigating the long-term effects of Lemtrada (alemtuzmab) in multiple sclerosis (MS) patients has revealed that the drug maintained outcomes, even in the absence of further treatment...Read more - http://www.ms-uk.org/lemtrada-shows-promising-results-rrms-patients-280217
Read more : Lemtrada shows promising results for RRMS patients | Views : 1638 | Replies : 0


Switching from Gilenya to Lemtrada could trigger MS activity

Switching from Gilenya to Lemtrada could trigger MS activity

According to research, switching treatments from Gilenya (fingolimod) to Lemtrada (alemtuzumab) can trigger significant and unexpected disease activity in MS patients...Read more - http://www.ms-uk.org/switching-gilenya-lemtrada-could-trigger-ms-activity-070217
Read more : Switching from Gilenya to Lemtrada could trigger MS activity | Views : 1440 | Replies : 0


Researchers reveal severe side effects from approved MS med.

Researchers reveal severe side effects from approved MS medication

According to recent study Multiple Sclerosis (MS) therapy alemtuzumab can trigger severe and unpredictable side effects. The team, led by Prof Dr Aiden Haghikia and Prof Dr Ralf Gold from the Department of Neurology of the Ruhr-Universität Bochum at St. Josef's Hospital, focused on two patients whose infusion of alemtuzumab significantly worsened symptoms...Read more - http://www.ms-uk.org/researchers-reveal-severe-side-effects-approved-ms-medication-240117
Read more : Researchers reveal severe side effects from approved MS med. | Views : 1579 | Replies : 0


Lemtrada decision

Hi all,
Just wondering how you made the decision to take the Lemtrada option? I'm being steering towards Lemtrada or Tysabri due to the nature of my RRMS.. I haven't taken any other medications yet so it certainly feels like i will be jumping in with both feet, I don't feel very comfortable about the amount of potential side effects. Though like all of you I'm unlucky to have MS I'm also very lucky to ...
Read more : Lemtrada decision | Views : 1862 | Replies : 2


 

Login  •  Register


Statistics

Total posts 243654 • Total topics 26791 • Total members 17879


Contact us | Terms of Service


cron